Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.

Jeon HJ, Oh TK.

Diabetes Metab J. 2011 Oct;35(5):529-35. doi: 10.4093/dmj.2011.35.5.529. Epub 2011 Oct 31.

PMID:
22111045
[PubMed]
Free PMC Article
2.

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.

Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Erratum in: Diabetes Obes Metab. 2009 Apr;11(4):405.

PMID:
19125777
[PubMed - indexed for MEDLINE]
3.

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Bosi E, Dotta F, Jia Y, Goodman M.

Diabetes Obes Metab. 2009 May;11(5):506-15. doi: 10.1111/j.1463-1326.2009.01040.x. Epub 2009 Mar 23.

PMID:
19320662
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
[PubMed - indexed for MEDLINE]
5.
6.

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.

Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G; Institution Investigators.

Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.

PMID:
22369287
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.

Lukashevich V, Prato SD, Araga M, Kothny W.

Diabetes Obes Metab. 2014 May;16(5):403-9. doi: 10.1111/dom.12229. Epub 2013 Dec 2.

PMID:
24199686
[PubMed - in process]
8.
10.

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.

Filozof C, Gautier JF.

Diabet Med. 2010 Mar;27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x. Erratum in: Diabet Med. 2013 May;30(5):632.

PMID:
20536495
[PubMed - indexed for MEDLINE]
11.
12.

Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study.

Yoon KH, Shin JA, Kwon HS, Lee SH, Min KW, Ahn YB, Yoo SJ, Ahn KJ, Park SW, Lee KW, Sung YA, Park TS, Kim MS, Kim YK, Nam MS, Kim HS, Park IeB, Park JS, Woo JT, Son HY.

Diabetes Metab J. 2011 Feb;35(1):26-33. doi: 10.4093/dmj.2011.35.1.26. Epub 2011 Feb 28.

PMID:
21537410
[PubMed]
Free PMC Article
13.

Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.

Blüher M, Kurz I, Dannenmaier S, Dworak M.

World J Diabetes. 2012 Sep 15;3(9):161-9. doi: 10.4239/wjd.v3.i9.161.

PMID:
23125906
[PubMed]
Free PMC Article
14.

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.

Yang W, Xing X, Lv X, Li Y, Ma J, Yuan G, Sun F, Wang W, Woloschak M, Lukashevich V, Kozlovski P, Kothny W; all investigators.

J Diabetes. 2014 May 14. doi: 10.1111/1753-0407.12169. [Epub ahead of print]

PMID:
24823599
[PubMed - as supplied by publisher]
15.
16.

Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.

Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W.

World J Diabetes. 2013 Aug 15;4(4):151-6. doi: 10.4239/wjd.v4.i4.151.

PMID:
23961326
[PubMed]
Free PMC Article
17.

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.

Odawara M, Hamada I, Suzuki M.

Diabetes Ther. 2014 Jun;5(1):169-81. doi: 10.1007/s13300-014-0059-x. Epub 2014 Mar 7.

PMID:
24604395
[PubMed]
Free PMC Article
18.

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

Rosenstock J, Samols E, Muchmore DB, Schneider J.

Diabetes Care. 1996 Nov;19(11):1194-9.

PMID:
8908379
[PubMed - indexed for MEDLINE]
19.

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

Bolli G, Dotta F, Colin L, Minic B, Goodman M.

Diabetes Obes Metab. 2009 Jun;11(6):589-95. doi: 10.1111/j.1463-1326.2008.01023.x. Epub 2009 Apr 13.

PMID:
19515179
[PubMed - indexed for MEDLINE]
20.

[Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].

Haluzík M, Veselá V, Gerle J, Brada M, Dohnalová L, Edelsberger T, Houdová J.

Vnitr Lek. 2013 Dec;59(12):1049-56. Czech.

PMID:
24350936
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk